dpp-4 inhibitors and glp-1 agonists How does sitagliptin work? mimetics Lesson: A Clinical Overview of

V.et al

Four models were established for the statistical analyses in this study

In diabetes care, GLP-1 receptor agonists are widely integrated into treatment guidelines and reimbursement systems

The semaglutide and tirzepatide trials changed that expectation: Semaglutide 2.4 mg once weekly produced average weight loss around 15% at ~68 weeks in adults without diabetes, with a substantial fraction of participants losing 1520% of baseline weight

Although there are currently no FDA-approved oral GLP-1 medications for weight loss, early data from clinical trials hint that a pill form could be as effective as its injectable counterparts

Efpeglenatide: The AMPLITUDE-O trial (2021) demonstrated a 27% MACE reduction (HR 0.73, 95% CI 0.580.92) in 4076 T2DM patients, with significant reductions in stroke and HF events [19]